Literature DB >> 8512390

Mitral valve operation via an extended transseptal approach.

N D Kon1, W Y Tucker, S A Mills, S W Lavender, A R Cordell.   

Abstract

The extended transseptal approach to the mitral valve has been used for 71 consecutive procedures. Four patients died; none had complications directly attributable to the exposure. Twenty underwent a primary reparative procedure; 30, a primary replacement procedure; and 21, a repeat procedure. Despite division of the sinus node artery, 26 of 32 patients with sinus rhythm preoperatively had sinus rhythm postoperatively; 4 had atrial fibrillation postoperatively. Twenty-seven of 37 patients with atrial fibrillation preoperatively had atrial fibrillation postoperatively; 8 had sinus rhythm postoperatively. Because the exposure provided by this extended transseptal approach is superior to that of standard approaches, we now use it routinely for mitral valve operations.

Entities:  

Mesh:

Year:  1993        PMID: 8512390     DOI: 10.1016/0003-4975(93)91081-w

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  The transseptal approach for mitral valve replacement revisited.

Authors:  F Santibáñez Escobar; G Serrano Gallardo; S Ramirez Marroquin; F Lopez Soriano; R Barragán García
Journal:  Tex Heart Inst J       Date:  1997

2.  Surgical removal of left atrial myxoma through mini sternotomy and the superior transseptal approach.

Authors:  A Marumoto; Y Ashida; H Maeta; S Ishiguro; H Kuroda; S Ohgi
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-03

3.  Combined superior-transseptal approach versus conventional approach for mitral valve surgery.

Authors:  H Tenpaku; S Wariishi; N Kanemitsu; M Okabe; T Nakamura
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2000-11

4.  Comparison of superior septal approach with left atriotomy in mitral valve surgery.

Authors:  Ebuzer Aydin; Akin Arslan; Mehmet Ozkokeli
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Jul-Sep
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.